Zhende Medical(SH:603301) Hua Xia Shi Bao·2025-11-12 01:38Core Viewpoint - The stock price of Zhend Medical surged by 306.26% within two months, raising its market value by over 20 billion yuan, despite a significant decline in net profit and financial concerns, leading to questions about whether this surge is a genuine value reassessment or mere speculation [1][4][10]. Group 1: Stock Performance - From early September to November 10, Zhend Medical's stock price increased from 23.98 yuan to 90.27 yuan per share, marking a year-to-date increase of 323.72% [1]. - The company achieved a 306.26% increase in stock price over 60 days, ranking first in the Shenwan Pharmaceutical and Biological sector [1]. Group 2: Financial Performance - In the first three quarters of 2025, Zhend Medical's net profit decreased by 33.91%, with cash on hand insufficient to cover short-term loans [1][8]. - The company's revenue for the first three quarters of 2025 only slightly increased by 1.88% to 3.184 billion yuan, while the net profit margin fell to 6.61% [8]. Group 3: Shareholder Dynamics - A key trigger for the stock surge was a 5% equity transfer to Sun Jimu at a price of 26.74 yuan per share, totaling 356 million yuan, with a commitment not to sell for 12 months [4][10]. - Following the transfer, Sun Jimu's stake rose to 5%, while the original shareholders, Zhejiang Zhend and Xuchang Garden, reduced their holdings [5]. Group 4: Market Reactions and Expert Opinions - Market analysts suggest that the stock price surge reflects a shift in valuation methods due to the involvement of industrial capital, with expectations of potential resource integration or strategic restructuring [10]. - Experts caution that reliance on short-term events for stock price movements may not sustain long-term business breakthroughs, emphasizing the need for technological innovation and product differentiation in the medical industry [10].